RIVOTRIL 0.25% Price

Overview

Welcome to Dwaey, specifically on RIVOTRIL 0.25% Drops (Oral) page.
This medicine contains an important and useful components, as it consists of Clonazepam.
RIVOTRIL 0.25% is available in the market in concentration 2.5mg/ml and in the form of Drops (Oral).

CHEPLAPHARMÊ ARZNEIMITTEL GMBH is the producer of RIVOTRIL 0.25% and it is imported from GERMANY, The most popular alternatives of RIVOTRIL 0.25% are listed downward .

Mode Of Action

Clonazepam reduces the nerve transmission in the motor cortex which suppresses the spike and wave discharge in absence seizures. Its mechanism is believed to be related to its ability to enhance the activity of GABA. Clinically, it improves focal epilepsy and generalised seizures.

Indication

• Epilepsy
• Anxiety disorders
• Panic disorder
• Status epilepticus
• Social phobia
• Migraines
• Parasomnia
• Restless legs syndrome
• Rapid eye movement
• Behavior disorder
• Spasticity
• Resistant depression
• Trigeminal neuralgia
• Nocturnal myoclonus
• Post traumatic stress disorder
• Insomnia and sleep disturbances
• Burning Mouth Syndrome

Precaution

Neonates, chronic pulmonary insufficiency, hepatic/renal dysfunction, porphyria, elderly; pregnancy and lactation. Lactation: Excreted in breast milk; not recommended

Side Effects

• >10% Somnolence (37%) 1-10% Abnormal coordination (5-10%)
• Ataxia (5-10%)
• Depression (5-10%)
• Dizziness (5-10%)
• Fatigue (5-10%)
• Memory impairment (5-10%)
• Upper respiratory infection (5-10%)
• Confusion (1-5%)
• Dysarthria (1-5%)
• Rhinitis (1-5%)
• Coughing (1-5%)
• Urinary frequency (1-5%)
• Impotence (1-5%)
• Decreased libido (1-5%) Frequency Not Defined Increased salivation
• Worsening tonic-clonic seizures Potentially Fatal: Salivary or bronchial hypersecretion leading to respiratory problems (children). May produce diminished reflexes or coma. Rarely
• blood dyscrasias.

Contra indication

Hypersensitivity to benzodiazepines, acute pulmonary insufficiency, acute narrow angle glaucoma.

Pregnancy and lactation

Pregnancy category: D

There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.